Soluble β-amyloid impaired the GABA inhibition by mediating KCC2 in early APP/PS1 mice

DOI Web Site 被引用文献2件 参考文献63件
  • Zhou Yuan
    Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
  • Cheng Yujie
    Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
  • Li Yong
    Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
  • Ma Jiyao
    First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Wu Zhihan
    First Clinical Medical College, Anhui Medical University, Hefei, Anhui, China.
  • Chen Yuenan
    Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.
  • Mei Jinyu
    Department of Otorhinolaryngology, Head and Neck Surgery, the Second Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Chen Ming
    Department of Pharmacology, School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.

この論文をさがす

抄録

<p>Alzheimer's disease (AD) is a neurodegenerative disorder, which has become the leading cause of dementia cases globally. Synaptic failure is an early pathological feature of AD. However, the cause of synaptic failure in AD, especially the GABAergic synaptic activity remains unclear. Extensive evidence indicates that the presence of soluble amyloid-β is an early pathological feature in AD, which triggers synaptic dysfunction and cognitive decline. Our recent study explored the relation of GABAergic transmission and soluble Aβ in early APP/PS1 mice. Firstly, we found soluble Aβ42 levels were significantly increased in serum, hippocampus and prefrontal cortex in 3-4 months APP/PS1 mice, which was much earlier than Aβ plagues formation. In addition, we found TNF-α and BDNF expression levels were increased, while KCC2 and GABAAR expression were decreased in 3-4 months APP/PS1 hippocampus. When we treated 3-4 months APP/PS1 mice with a potent γ-secretase inhibitor, LY411575, which can reduce the soluble Aβ42 levels, the TNF-α and BDNF protein levels were decreased, while KCC2 and GABAAR levels were increased. In conclusion, our study suggested soluble Aβ may impaired the GABA inhibition by mediating KCC2 levels in early APP/PS1 mice. KCC2 may be served as a potential biomarker for AD. </p>

収録刊行物

  • BioScience Trends

    BioScience Trends advpub (0), 330-340, 2021

    特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会

被引用文献 (2)*注記

もっと見る

参考文献 (63)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ